This Correction resolves the prior Expression of Concern for the linked article [1,2].
Following the publication of the article and Expression of Concern [1,2], PLOS investigated the concerns pertaining to the reported ethical oversight and the article’s adherence to PLOS’ research ethics policies and PLOS’ Competing Interests policy.
Following the editorial investigation, the concerns pertaining to the article’s adherence to PLOS’ research ethics policies were dismissed.
The authors did not respond to the journal’s queries about competing interests. Based on publicly available information, the Editors update the article’s Competing Interests statement to: At the time this article was submitted, DR was listed as a co-founder and member of the scientific council of Arthrobac Pharma.
With this update, the PLOS Genetics Editors consider the issues described in [2] to be resolved. This Correction supersedes the prior Expression of Concern [2].
References
- 1. Amanzougaghene N, Fenollar F, Nappez C, Ben-Amara A, Decloquement P, Azza S, et al. Complexin in ivermectin resistance in body lice. PLoS Genet. 2018;14(8):e1007569. pmid:30080859
- 2. The PLOS Genetics Editors. Expression of Concern: Complexin in ivermectin resistance in body lice. PLoS Genet. 2022;18(12):e1010531. pmid:36512548
Citation: The PLOS Genetics Editors (2026) Correction: Complexin in ivermectin resistance in body lice. PLoS Genet 22(7): e1012258. https://doi.org/10.1371/journal.pgen.1012258
Published: July 30, 2026
Copyright: © 2026 The PLOS Genetics Editors. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.